-
Story
Why advocating for your MS is so important -
Story
From black holes to AI driven drug discovery – collaboration wins the day -
Press ReleaseNovartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
-
Story
Beacon of Hope lights the way for a more equitable future -
Press ReleaseSandoz presents compelling investment proposition as standalone company at Capital Markets Day
-
Story
The future of medicine is here -
Press ReleaseNovartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
-
Press ReleaseSandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
-
Press ReleaseAktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
-
Press ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
-
Press ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
-
Press ReleaseNovartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness